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       ABSTRACT 
 
Subarachnoid hemorrhage (SAH) secondary to ruptured cerebral aneurysm is a complex trait, with both genetic and environmental risk 
factors playing an important part. The 30-day mortality rate of patients with SAH is 40% to 44%, with survivors suffering from major 
disability. Despite the high incidence and catastrophic consequences of a ruptured cerebral aneurysm and the fact that there is considerable 
evidence that predisposition to cerebral aneurysm has a strong genetic component, very little is understood with regard to the pathology and 
pathogenesis of this disease. Recent advances in molecular genetics provide evidence that genetic variants of different candidate genes are 
associated with the occurrence of cerebral aneurysm. This article reviews the evidence supporting a genetic predisposition to SAH from 
cerebral aneurysm, the conditions commonly associated with cerebral aneurysm, and the search for genetic risk factors. (Kor J Cerebrovascular 
Surgery 5:12-6 2003) 
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Introduction 
 
Rupture of cerebral aneurysms followed by subarachnoid 
hemorrhage(SAH) is a serious disease associated with high 
mortality and morbidity. Treatment modalities comprise mic-
rosurgery and endovascular techniques, eg, Guglielmi deta-
chable coils or intraluminal stents. Optimization of surgical 
procedures and anesthesia as well as advances in emergency 
and intensive-care medicine and radiological diagnostics 
have all resulted in a better clinical course and outcome for 
SAH patients. However, SAH continues to represent a serious 
health problem and the cause of major annual costs.  
While the incidence of other types of stroke has declined 
in recent decades, primarily because of improved detection 
and management of hypertension, the incidence of SAH has 
remained relatively constant. Despite the high incidence of 
cerebral aneurysm and the catastrophic consequences of rup-
ture, relatively little is understood with respect to molecular 
pathology and pathogenesis. This lack of information has 
severely hampered efforts to identify individuals at risk of a 
cerebral aneurysm and to define novel points of therapeutic 
intervention and is largely due to the difficulty in obtaining 
suitable aneurysmal tissue specimens for use in these an-
alyses. The few studies that have attempted to investigate the 
molecular basis of cerebral aneurysm have focused on a 
limited number of biological markers that have been studied 
in isolation.1)7) Also, several candidate genes have been 
analyzed which, because of the function of the encoded 
proteins, might contribute to the pathogenesis of cerebral 
aneurysm. Local genetic variants in the vessel wall may 
affect endothelial cells or repair or remodeling processes in 
deeper layers. In this article, we review current models for 
the genesis of cerebral aneurysms.  
 
1. Studies of candidate genes for cerebral aneurysms 
 
1) Collagen type III 
Given the absence of collagen type III and the great 
destruction of elastin fibers and collagen fibers seen within 
the aneurysmal wall, research efforts have focused on these 
elements as well as the regulation and degradation of these 
elements. Although several instances of abnormal collagen 
type III production and procollagen production appear in the 
literature,3)11)19)23) a sequence analysis of the collagen type III 
gene performed on spontaneous cerebral aneurysm failed to 
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find a mutation that could explain the decreased and 
abnormal production of collagen type Ⅲ.9) Kuivaniemi et 
al9) performed detailed DNA sequencing analyses on 58 
patients with cerebral aneurysms or cervical artery dissec-
tions. In an analysis of 3,232 nucleotides per patient, muta-
tions in the coding sequences were excluded in 40 individuals 
with aneurysm. In fact, only 2 nucleotide variations were 
found in the cohort of 58 individuals, but procollagen syn-
thesis did not differ among these patients. This study strongly 
suggests that abnormalities of type III collagen are not likely 
to be a common cause of cerebral aneurysm. 
 
2) Matrix methalloproteinases  
  Matrix methalloproteinases(MMP) are a family of enzy-
mes that includes collagenase, gelatinase, and elastases. Vessel 
wall destruction would be increased if an abnormally high 
level or potent form of the MMPs were present or if there 
were a decrease in the tissue inhibitors of the MMPs(TIMP). 
Much of the literature is focused on the presence of MMPs 
and TIMPs in aortic aneurysm. Yet a few studies regarding 
the importance of MMPs and TIMPs in cerebral aneurysm 
are also available. MMP-2 and MMP-9 are also known as 
gelatinase A and B because of their strong activity against 
extracellular matrix gelatin(Fig. 1).  
Kim et al7) reported that levels of MMP-9 as well as 
TIMP are markedly increased in the aneurysmal wall com-
pared with extracranial arteries. This finding suggests that 
abnormalities in MMPs are a local rather than a systemic 
phenomenon and that the increase in destruction is not 
secondary to low levels of TIMP. Bruno et al1) compared 
aneurysmal tissue with the basilar artery of control autopsy 
subjects and found that MMP-9 was heterogeneously distri-
buted in 40% of cases of aneurysm, whereas it was diffusely 
distributed in the control patients. They also reported that 
64% of patients had MMP-2 activity identified, compared 
with only 14% of controls. 
From the same study group, Todor et al32) reported that 
increased serum levels of pro-MMP2 occur in some patients 
with cerebral aneurysm. This increase may be secondary to 
Fig. 1. Interaction of matrix metalloproteinases (MMP), especially MMP-2 and MMP-9, which might contribute ot deg-radation of a 
vessel wall by remodeling of the extracellular matrix (ECM). After processing in endoplasmic reticulum, the pro-enzyme is secreted in 
an inactivated form (zymogen) by different cell types like endothelial cells, smooth muscle cells or fibroblasts. In the activation of pro 
MMP-2 tow pathway are probably involved. Binding to transmembrane MMPs (membrane-type-1 MMP and MT2-MMP) and the 
plasmin activator system leads to a final active enzyme. However, plasmin does not seem to act directly on MMP-2 but by means of 
other MMPs, especially MMP-9. By destruction of glycoprotein like fibronectin and tenascin, plasmin may contribute to ECM re-
modeling more directly. U-PA：urokinase-type plasminogen activator, t-PA：tissue-type plasminogen activator, TIMP：tissue inhibitor 
of metalloproteinases. 
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other conditions that are associated with aneurysm. For 
example, smokers are known to develop emphysema, atheros-
clerosis, and cerebral aneurysm, and it is possible that 
smoking behavior itself may induce expression of pro-
MMPs. 
In a sequence analysis of the MMP-9 promotor region 
among 36 individuals with aneurysms, Peters et al21) report 
that a single polymorphic site was present(the remainder of 
the genetic code being identical to controls). At this site, a 
variable number of cytosine-adenine(CA) repeats were seen 
with 23 repeats associated with internal carotid artery for-
mation. This difference, however, was somewhat small, with 
18% of cases having the 23 repeat alleles, compared with 
9% of controls. In addition, having 22 repeats, a difference 
of only 1 repeat, showed the opposite relationship(9% of 
cases compared with 19% of controls having 22 CA repeats). 
Increased number of CA repeats has been associated with 
increased MMP-9 expression. However, 2 subsequent studies 
have failed to find an association with higher CA repeats and 
cerebral aneurysm. Yoon et al33) examined a Finnish popula-
tion of 57 cases and 174 controls and found no significant 
association between these repeats and cerebral aneurysm. In 
their study, all cases of aneurysms had a family member with 
a history of cerebral aneurysm. Zhang et al35) recently repor-
ted on 92 cases of SAH compared with 158 controls and also 
did not find an increased association of CA repeats. It may 
be possible that increased MMP-9 levels are secondary to 
environmental risk factors such as smoking or hyper-tension 
and not attributable to abnormalities in the MMp-9 gene. 
 
3) Alpha-1-antitrypsin 
Alpha-1-antitrypsin(AT) is a glycoprotein that inhibits 
proteases. AT deficiency is known to cause emphysema and 
liver disease. AT is also an elastase inhibitor, and mutations 
may lead to aneurysm formation. The normal variants of the 
AT gene are commonly referred to as PiM1, PiM2, and 
PiM3, and PiZ and PiS are the abnormal variants. The PiZ 
variant is associated with very low levels of AT and very low 
functional activity in he homozygous state(approximately 
15% of normal). PiS is associated with less protein and less 
functional activity in the homozygous state(approximately 
60% of normal). 
Schievink et al27) examined 362 patients with AT deficiency, 
and found 3 cases of ruptured cerebral aneurysm and 1 case 
of spontaneous dissection. They reported that 3 patients were 
heterozygous for the PiZ mutation and one was homozygous 
(PiZZ). This led to a study of 100 consecutive patients with 
cerebral aneurysm, which found that 16% of cases were 
heterozygous for either the PiS or PiZ alleles, compared with 
only 7% of 904 people from Minnesota(OR=2.56；95% CI, 
1.32 to 4.75).25) 
However, several studies have been unable to confirm 
these associations. St. Jean et al28) reported that among 72 
cases of cerebral aneurysm(26 from Pittsburgh and 46 from 
London), 2 patients carried the PiS allele and 4 carried the 
PiZ allele(includes 1 patient with PiSZ). These results were 
not found to be significantly increased compared with popula-
tion-based controls from Pittsburgh. Elzouki et al4) reported 
that of 30 consecutive individuals with known homozygous 
PiZZ AT deficiency, none of the cases were found at autopsy 
to have had a cerebral aneurysm or cervical dissection. 
 
4) Angiotensin I-converting enzyme 
Angiotensin I-converting enzyme(ACE) converts angio-
tensin I to angiotensin II, which is a potent vasoconstrictor as 
well as a regulator of aldosterone and catecholamine syn-
thesis.10)20)34) The ACE locus(17q23) has two major forms. 
The D or deletion allele has been associated with higher 
circulating ACE levels13) and has been associated with car-
diovascular disease and left ventricular hypertrophy.2)5) Cu-
riously, several studies have found that the D allele is actually 
less common among cases of ruptured aneurysm compared 
with controls. Takenaka et al31) examined 83 patients with 
cerebral aneurysm compared with 104 control subjects. They 
found that the D/D genotype was slightly increased among 
the aneurysm group(46%) compared with the control group 
(41%). A separate group in Cambridge, England, identified 
a similar phenomenon. In their group, the I allele was 
associated with aneurysm risk over the D allele(OR=1.3；
95% CI, 1.02 to 1.65).6) It is unclear whether ACE alleles 
are directly associated with SAH as a candidate gene or 
whether the alleles are in linkage disequilibrium with a 
causative gene.  
Several other candidate genes have appeared in the lite-
rature, but thus far, they have not been confirmed by sub-
sequent studies.8)12)14)17-19)24-26)29-31) Recently, Peters et al22) 
used a global gene expression analysis approach(SAGE-
Lite) in combination with novel data-mining approach to 
perform a high resolution transcript analysis of a single 
cerebral aneurysm. The significant overexpression of genes 
involved in extracellular matrix components(eg, COL3A1, 
COL1A1, COL1A2, COL6A1, COL6A2, elastin) and genes 
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involved in extracellular matrix turnover(TIMP-3, OSF-2), 
cell adhesion and antiadhesion(SPARC, hevin), cytokinesis 
(PNUTL2), and cell migration(tetraspanin-5)(Table 1). 
 
2. Linkage studies for cerebral aneurysm 
Linkages studies use polymorphic markers(genes that are 
variable within the population) and the presence or absence 
of disease among affected and unaffected relatives to de-
termine whether a specific marker occurs more often than 
expected by chance among affected individuals. Given the 
high mortality rate of SAH, the acquired nature of the 
disease, and the strong environmental covariants, a linkage 
study faces tremendous challenges both in data collection 
and in analysis.  
In 1998, Olson et al15) reported a genome-wide screen 
among 48 affected sibling pairs taken from 264 siblings of 
85 cerebral aneurysms probands in Finland. Two regions had 
multipoint maximum LOD scores(MMLS) greater than 2.0：
chromosome 19(MMLS=2.63) and chromosome X(MMLS 
=2.08). Four additional regions had the highest MMLS, and 
this region is one in which numerous cerebrovascular and 
cardiovascular gees are located. Recently Onda et al16) re-
ported a genome-wide linkage study among 104 Japanese 
affected siblings pairs. They identified evidence of linkage 
on chromosome 5q22-31(maximum LOD score [MLS], 
2.24), 7q11(MLS, 3.22) and 14q22(MLS, 2.31). The best 
evidence of linkage was detected at marker D7S2472 in the 
vicinity of the elastin gene(within 400 kb). Notably, linkage 
was not apparent in the regions reported by Olson et al.15) 
Although no single polymorphism was found to have a clear 
association with cerebral aneurysm, patients homozygous for 
the major allele of Intron 20(M) and the minor allele for 
intron 23(m) were at high risk(OR for Mm=4.39, 95% CI, 
2.6 to 12) for IA. Several other associations were also found. 
The association of mutations within the elastin gene is a 
compelling one given that elastin and its destruction are key 
elements of aneurysm formation. This study did not report 
analysis may occur, and confirmation of these findings in 
other populations is required. 
 
 Conclusions 
 
Future investigations will focus on the genetic background 
of aneurysm pathogenesis. It is unlikely that there is only 
one gene affected since the development of an aneurysm is 
clearly a complex multifactorial event. Linkage analysis is a 
suitable method for investigating the genetic origin of a disease. 
Table 1. Exmaples of genes that are overexpressed in cerebral aneurysm and are of biological significance and putative function of
specific gene products 
Gene Ratio, ICA：STA Putative function 
Fibronectin  443：4 ECM constituent 
Collagen type III α-1  034：7 ECM constituent 
Collagen type I α-2  020：1 ECM constituent 
Collagen type I α-1  033：1 ECM constituent 
Collagen type VI α-1  013：1 ECM constituent 
Collagen type VI α-2  009：1 ECM constituent 
Collagen type IV α-1  005：0 ECM constituent 
Elastin  005：0 ECM constituent 
TIMP-3  020：0 ECM constituent 
OSF-2  013：0 MMP activation/ECM remodeling 
βig-h3  006：0 Collagen bridging/ECM 
CTGF  006：0 TGF-β-induced collagen synthesis/ECM 
SPARC  029：0 Antiadhesive glycoprotein/ECM remodeling 
Hevin  006：0 Antiadhesion 
β-Gal-binding lectin  0026：7 Cell adhesion, proliferation/migration, immunomodulation 
cdc-rel2a/PNUTL2  014：0 Cytokinesis 
Tetraspanin-5  005：0 Cell proliferation/Cell migration 
Cathepsin B  013：1 Lysosomal protease 
Cathepsin D  004：0 Lysosomal protease 
Vinculin  005：1 Adhesion plaques 
c-Abl 007：0 Adhesion plaques 
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However, this requires a large number of affected families. 
Another method is the analysis of candidate genes. The 
genes of interest encode for proteins or enzymes, which are 
essentially involved in biochemical pathways known to be 
part of aneurysm pathogenesis like arteriosclerosis or extra-
cellular matrix remodeling.  
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